Table 1

Baseline characteristics of ASCEND analysis population

Baseline characteristicsSEL analysis populationITT population
Placebo
(n=292)
Natalizumab
(n=308)
Placebo
(n=448)
Natalizumab
(n=439)
Age, mean (SD)47.8 (7.6)47.4 (7.2)47.2 (7.8)47.3 (7.4)
Female, %65626362
Patients with ≥1 Gd+ T1 lesion, %19282226
Mean (SD) T2LV, cm316.5 (16.7)18.1 (18.5)16.2 (16.4)17.4 (17.6)
Normalised brain volume, mean (SD), cm31429.8 (81.64)1422.0 (81.75)1425.8 (83.1)1420.9 (82.8)
  • ASCEND SEL analysis population represents the subset of the ITT population that had available T1-weighted and T2-weighted images at all timepoints from baseline to week 108 (including weeks 24, 48, 72 and 96).

  • Gd+, gadolinium enhancing; ITT, intention to treat; SEL, slowly expanding lesion; T1, T1-hypointense; T2LV, T2-hyperintense lesion volume.